|
|
Improved humanised antibody to human α9-integrin Invention describes polynucleotide, expression vector, host cell and production method of humanised antibody together with their use, as well as medical preparation against rheumatoid arthritis, prophylaxis or treatment method of rheumatoid arthritis and use of humanised antibody at production of pharmaceutical preparation for prophylaxis or treatment of rheumatoid arthritis. This invention can be used in therapy of human diseases associated with α9 integrin. |
|
Oxazolopyrimidines as agonists of edg-1 receptor Invention refers to derivatives of oxazolopyrimidine in any of their stereoisomeric forms, or in the form of a mixture of stereoisomeric forms specified in Claim 1. |
|
Substituted 4-aminocyclohexane derivatives Invention relates to novel 4-aminocyclohexane derivatives, having affinity for the µ- opioid receptor and ORL1 receptor. In formula |
|
Method of treating nosocomial sinusitis in patients of resuscitation and intensive care units Invention refers to medicine. Treating nosocomial sinusitis in resuscitation and intensive care units is ensured by nasal cavity clearance and sinus irrigation according to the common technique using a Kulikovsky's needle. The solution of polymyxin E in the concentration of 133 mcg/ml is introduced for 10 minutes before sinus administration of a photosensitiser that is methylene blue 20 ml in the concentration of 15 mcg/ml. The contents are aspirated with a syringe. The sinus mucosa is exposed to laser light through a dissipative light guide introduced through the Kulikovsky's needle at wave legnth 660 nm, power 500 mWt, emission length 23.5 minutes. |
|
|
Invention refers to medicine, particularly to dentistry, and may be used for the local treatment and prevention of the primary dental pathologies in hemodialysis-dependent children suffering a terminal stage of the chronic renal failure. That is ensured by using a chewable substrate containing bee wax 4.0 g and cultivated angelica root 0.4 g 3 times a day for 15 minutes for 2 weeks. |
|
|
Method for reducing and managing bronchial asthma status Invention refers to medicine, namely to emergency medicine, and may be used for reducing and managing the bronchial asthma status. That is ensured by introducing human urotensin 2 (hU) antiserum that is a hormone of the caudal neurosecretory system (CNSS) one a day intracutaneously into a palmar surface of the arm in 2-3 points in a dose of 0.1- 0.2 ml and 25% magnesium sulphate intravenously in a dose of 5-10 ml twice a day in a combination with intravenous glucocorticosteroids and bronchial spasmolytic inhalations. |
|
Drug preparation in form of orally dispersible tablet and method for making drug preparation Invention refers to medicine and chemical-pharmaceutical industry, namely to drug preparations used in various spastic intestinal and pancreatic-biliary conditions, especially in irritable bowel syndrome, and to methods for making them. The drug preparation in the form of an orally dispersible tablet characterised by the fact that it contains a combination of hyoscine butyl bromide and diclofenac or its sodium salt in complex with polacrilin potassium in ratio of diclofenac or its sodium salt and polacrilin potassium of 1:2, and pharmaceutically acceptable additives containing mannitol, aspartame and crospovidone. Polyvinyl pyrrolidone K30, a flavouring agent and anhydrous colloidal silicon dioxide. |
|
Hair growth product (versions) and methods of treating alopecia Invention refers to medicine and cosmetology, and represents a composition for treating or preventing alopecia in the form of a gel containing sodium salt of non-fractionated heparin 0.08-0.8% , lipid nanocomplex emulsion 0.15-3%, gel former 0.5-2%, emulsifier 0.1-0.2%, neutralising agent 0.03-1.3%, preserving agent 0.01-0.03%, and a solvent specified in a group consisting of water, or polyol - the rest. |
|
|
Pharmaceutical composition in form of skin protection paste Invention refers to pharmaceutical composition in the form of a skin protection paste. The composition contains a film-forming agent representing poly(butyl methacrylate-co-methyl methacrylate), hydrocolloid, a filling agent, a softening agent and an alcoholic diluent in the certain proportions. |
|
|
Oral care product and method for using and preparing it Invention refers to methods of treating early enamel loss. The presented method of treating or reducing early enamel caries involves the dental application of an effective amount of a dental composition wherein the dental composition has a main formulation containing dicalcium phosphate, wherein the dental composition additionally contains arginine in the free or salt form, and an effective amount of fluoride, wherein arginine is found in the amount of 2 to 10 wt % of total weight of the dental composition. |
|
|
Method for orthopaedic treatment of patients with removable laminar denture Invention refers to medicine, namely to dentistry and may be used in the orthopaedic treatment of the patients with partial and/or complete denture defects using removable laminar dentures. A method involves making the removable laminar dentures, taking the oral hygienic measures, cleaning the removable laminar dentures. Ozonised olive oil is applied on an internal surface of the prosthetic basis that is followed by applying the prosthesis on the denture defect for 10-30 minutes. The prosthesis with ozonised olive oil applied on the internal surface of the basis is attached once a day for 8-16 days. |
|
Sulphonamide compounds and use thereof Invention relates to sulphonamide compounds of formula or pharmaceutically acceptable salts thereof, wherein A is phenyl, optionally substituted with 1 or 2 halogen atoms, C1-6 alkyl group, trifluoromethyl group, C1-6 alkoxy group or -SCH3 group, thiophenyl, optionally substituted with a C1-C6 alkyl group or a halogen atom, pyridinyl, optionally substituted with a halogen atom, naphthalenyl or dihydroindenyl; R1 denotes the following formulae or [in formulae (R1a) and (R1b) Ar1 denotes the following formulae , or (each R5 and R6 independently denotes a hydrogen atom, a halogen atom, a C1-6 alkyl group optionally substituted with up to three halogen atoms, C1-6 lower alkoxy group optionally substituted with up to three halogen atoms); Ar2 denotes the following formulae , or (each R7 and R8 independently denotes a hydrogen atom, a hydroxyl group, a halogen atom, a C1-6 alkyl group optionally substituted with up to three halogen atoms or a C1-6 lower alkoxy group optionally substituted with up to three halogen atoms, an amine group, a nitro group, a C2-6 acyl group, or R7 and R8 together form -CH2CH2O-; R9 is a hydrogen atom or - J-COOR10; J is a covalent bond, alkylene containing 1 to 5 carbon atoms, alkenylene containing 2 to 5 carbon atoms or alkynylene containing 2 to 5 carbon atoms, where one carbon atom in said alkylene groups can be substituted with an oxygen atom, a sulphur atom, NR11, CONR11 or NR11CO in any chemically acceptable position; R11 is a hydrogen atom; and R10 is a hydrogen atom); and p equals 0 or 1]; R2 is a C1-6 alkyl group; each R3 and R4 is independently a C1-6 alkyl group; * denotes an asymmetric carbon atom; and m equals an integer from 1 to 3. The invention also relates to a medicinal agent for stimulating PTH secretion. |
|
Therapeutic agent for treating rhinitis Invention refers to pharmaceutics and medicine and concerns preparing a fast-acting effective and safe agent for treating rhinitis. Solving the problem provides the agent for treating rhinitis, particularly allergi rhinitis containing C-type natriuretic peptide (CNP) and/or B-type natriuretic peptide (BNP) as an active ingredient. |
|
Invention refers to pharmaceutical industry, namely to a method for producing a therapeutic biologically active preparation for treating dyspepsia in newborn calves. The method for producing a therapeutic biologically active preparation for treating dyspepsia in newborn calves consisting in the fact that the multiseptate gastric content and amniotic placental fluid are sampled from female foetus; the multiseptate gastric tissue is homogenised, combined with the amniotic placental fluid, settled, filtered, centrifuged; a produced liquid fraction is combined with the multiseptate gastric content in the certain environment. |
|
|
Invention refers to a pharmaceutical composition with anti-inflammatory, cardio- and chondroprotective activity, action preventing gastropathies caused by non-steroidal anti-inflammatory drugs. The above composition contains sodium diclofenac 5 - 25%, quercetin in the form of dihydrate or an anhydrous substance 10 - 40%, polyvinylpyrrolidone 10 - 50%, sodium lauryl sulphate 0.25 - 10%, microcrystalline cellulose 20 - 40%, croscarmellose sodium salt 1 - 15% and magnesium stearate 0.25 -5.0% at total weight of the composition. The invention also concerns the method for preparing the specified compound. |
|
Method for rehabilitation of patients suffering osteoarthrosis Invention refers to medicine, namely rheumatology, balneotherapy and physiotherapy. The method involves the integrated treatment. There are prescribed sulphide bath with the total hydrogen sulphide concentration of 158 mg/l, the free hydrogen sulphide concentration of 108 mg/l at temperature 36-37°C. The length of the first 2-3 baths is 6-8 minutes. The length is to be increased to 8-12 minutes. The baths are taken within the period of 10.00 to 12.00 every second day. The therapeutic course is 10-12 procedures. On the same days, within the period of 14.00 to 16.00, therapeutic exercises are done, and the climatic and landscape therapy is prescribed. On the days free from taking baths, within the period of 10.00 to 12.00, the EHF therapy is prescribed to cover biologically active points (BAP) at frequency 40-43 GHz. The points G-41, 3E-5 are exposed. The hip osteoarthrosis requires the exposure on the points G-29, G-30. If observing the upper extremity osteoarthrosis, the points 3E-4, Du-4, Du-5, Di-5 are covered. In case of the knee osteoarthrosis, the points M-34, M-35, Le-7, Le-8 are exposed. The length of the exposure covering one BAP makes 5-6 minutes. The total length of the procedure is 20-30 minutes. On the same days within the period of 14.00 to 16.00, high-mineralised average sulphide mud is applied at temperature 38-40°C on the involved joints and respective spinal reflexogenic zones. A single procedure covers not more than 2-3 greater joints. The length of one procedure is 20-25 minutes. The therapeutic course is 8-10 procedures. The total length of the rehabilitation makes 20-24 days. |
|
Method for rehabilitation of patients suffering deforming arthrosis of knee joints Invention refers to medicine, namely to - arthrology, physiotherapy, balneology. The method involves physical methods of therapy, therapeutic exercises, massage, acupuncture and phytotherapy. The patients are trained to give a self-massage of the knee joints additionally during the resort therapy and after the termination of the rehabilitation. From the 1st to 10th day of the therapeutic course patient's knee joint is exposed to polychromatic polarised light at 20 cm for 6 minutes. The patients take 10 iodine-bromine baths at temperature 37°C for 10 minutes. From the 1st to 5th therapeutic days, the patients do combined therapeutic exercises; their lower extremities are massaged manually for 10 minutes. From the 6th to 15th days, the knee joints are exposed to sinusoid modulated currents (SMC) at modulation frequency 100 Hz, at a depth of 50 - 70%, current intensity to moderate vibration for 7 minutes. From the 6th to 10th days, the braking acupuncture follows by giving a 1-2-minute massage of the points 10RP, 9RP, 36E, 34E by introducing a needle for 30 seconds and by giving a point massage of cheng-fu, cuan, yang-lin-cuan, zu-sang-li, wei-yang, cheng-shan, chung-feng, hun-lun, nei-ting. The patients take a herbal infusion. From the 11th to 15th days, the knee joints are exposed to decimetric waves (DMW). That is followed by a hydro-massage of the lower extremities and lumbar region for 15 minutes up to 3 atm. Thereafter, the 10-minute post-isometric relaxation of the quadriceps muscle of thigh is applied. The patients do the complex of weight reduction exercises and take the herbal infusion. From the 16th to 20th day, the mud applications on the knee joints are prescribed at temperature 42°C for 30 minutes. If suffering gonarthrosis, the patients do the complex of therapeutic exercises. That is followed by the paravertebral vacuum therapy of the vertebral column. The 10-minute knee joint traction is applied. The patients take 20 g of the herbal infusion. |
|
|
Subpeptides for induction of synthesis of proteins of extracellular matrix Peptides consist of four amino-acid residues that are used for stimulation of collagen production with fibroblast. |
|
Therapeutic substituted cyclopentanes Invention relates to a novel compound of formula where Y is or or a pharmaceutically acceptable salt thereof. |
|
Method of treating acute pneumonias in debilitated patients living in industrial cities Invention refers to medicine, namely to pulmonology and physiotherapy, and may be used for treating acute pneumonias in debilitated patients living in industrial cities. That is ensured by 10 daily ultrasonic inhalations of 1% placenta hydrolysate at temperature 35°C for 10 minutes on an empty stomach or 40-60 minutes after meals. The inhalations are followed by the exposure to an ultra-high frequency electric field generated by automatically resonating UHF-80-3 Undaterm apparatus of output power up to 80 Wt, high-frequency oscillation frequency 27.12±0.6 MHz. The UHF exposure covers a patient sitting of a wooden chair. Condenser plates, each of the diameter 180 mm spaced 3 cm are placed on front and back surfaces of a chest above the inflammation centre from each side. An UHF dose is low-heat, has a power of 40-60 Wt; the procedure length is 10 minute; the therapeutic course makes 10 daily procedures. After 30 minutes, the UHF exposure is followed by medicine electrophoresis through 5% placenta hydrolysate applied on one of the temporary spacers. The exposure is generated by Potok-1 apparatus having current intensity 15-20 mA; the procedure length makes 20 minutes; the therapeutic course is 10 daily procedures with the patient lying on back on a bed. Two electrodes of the same size 10x15 cm are placed in a projection of the pathological centre, i.e. the first electrode is placed on the right or on the left on the back, and the second one - on the right or on the left at the front. |
|
|
Method of treating skin diseases in sheep Invention refers to medicine, namely veterinary science, and may be used for treating skin diseases in sheep. That is ensured by preparing the affected skin. The affected skin is prepared with 70% ethanol. That is followed by processing the affected skin with electrochemically activated water using a spray head first with an acid fraction at pH 3.0 in the amount of 20-30 ml per the surface of 10 cm2 for 10-15 seconds at 15-20 cm. That is followed by keeping for 25-30 minutes and processing with an alkali fraction at pH 11.00 in the amount of 20-30 ml per the surface of 10 cm2 for 10-15 seconds at 15-20 cm. The skin is processed twice a day. |
|
|
Method for preventing premature delivery Invention relates to medicine, namely to obstetrics and gynaecology. What is presented is administering a pharmaceutical formulation containing pharmaceutically active relaxin H2 into pregnant women. |
|
New pharmaceutical compositions Invention refers to pharmaceutical industry and represents a pharmaceutical composition for prevention the formation of postoperative cicatrices, surgical adhesions and keloids, containing a biologically active peptide containing an amino acid sequence SEQ ID NO:56, wherein the peptide is found in the concentration of 0.1 mg/ml to 100 mg/ml; and hyaluronic acid with high molecular weight, or a pharmaceutically acceptable salt of hyaluronic acid with high molecular weight, wherein hyaluronic acid with high molecular weight has an average molecular weight more than 300000 Da, and wherein hyaluronic acid is found in the concentration of 0.1 to 10% (wt/wt). |
|
Method of treating localised forms of psoriasis Method relates to medicine, particularly to dermatology, and may be used in treating localised forms of psoriasis. That is ensured by administering 1% glutoxim 0.1 ml along the perimetre of a psoriasis patch at 1.0-1.5 cm once a day for 7-12 procedures. |
|
|
Invention refers to an antacid and laxative tablet that contains magnesium oxide particles of the diameter of 0.5 to10 mcm as a main ingredient in the amount of 85 to 96 wt %. The claimed tablet contains crystalline cellulose 2-8 wt % as a binding agent, sodium croscarmellose 0.8-2.5 wt % as a disintegrating agent 1, insoluble polyvinyl pyrrolidone 1-3.5 wt % as a disintegrating agent II and a lubricant 0.5-2 wt %. The invention also refers to a method for preparing the above tablet that involves the mixing of the magnesium oxide particles, crystalline cellulose and the lubricant, and the dry granulation of the prepared mixture to produce the magnesium oxide granules, the mixing of crystalline cellulose, insoluble polyvinyl pyrrolidone and the lubricant with the magnesium oxide granules, and the tableting of the produced granules. The invention also refers to using the claimed tablet for antacid and laxative applications. |
|
Compounds and methods for uric acid reduction Present invention refers to a method for reducing the blood uric acid concentration in a mammal patient, or increasing the uric acid discharge in a mammal patient involving administering 2-(3-(2,6-dimethylbenzyloxy)-4-methylphenyl)acetic acid or a pharmaceutically acceptable salt thereof in the effective amount into the patient. Besides, the declared invention is used in a method of treating or preventing a number of conditions, including uratic arthritis, hyperuricemia, the uric acid levels exceeding those normally diagnosed as hyperuricemia, renal dysfunction, renal calculi, cardiovascular disorder, risk of cardiovascular disorder, tumour lysis syndrome and cognitive impairment. |
|
Compounds and methods for uric acid reduction Present invention refers to a method for reducing the blood uric acid concentration involving administering a compound of formula I or a pharmaceutically acceptable salts thereof. Besides, the present invention refers to a method of treating preventing a number of conditions, including uratic arthritis, hyperuricemia, the uric acid levels exceeding those normally diagnosed as hyperuricemia. |
|
Pharmaceutical composition for treating gastroesophageal reflux disease Invention refers to pharmaceutical industry and represents pharmaceutical composition for treating gastroesophageal reflux disease, containing at least one proton pump inhibitor and at least one probiotic, wherein the proton pump inhibitor is taken in the amount of 0.05-25 wt % in the composition; and the probiotic is taken in the amount of 10-95 wt %; additive agents up to 100 wt %. |
|
|
Composition and method of treating pathological skin conditions Invention refers to cosmetic industry and represents a non-foaming cosmetic composition of an oil-in-water emulsion containing (i) retinol, (ii) at least one polar emollient specified in a group consisting of propylene glycol stearyl ester, propylene glycol isostearate and mixtures thereof (iii) at least one non-polar emollient specified in a group consisting of aromatic or linear esters, Gerbe ester, mineral oils, squalane, isohexadecane, squalene, liquid paraffin and mixtures thereof with the weight ratio of the above polar emollient and the above non-polar emollient is found within the range of approximately 95 to 5 to approximately 40 to 60. |
|
Invention refers to synthetic peptide amides of formula I |
|
Heterocycle-substituted piperazino-dihydrothienopyrimidines Invention relates to dihydrothienopyrimidinesulphoxides of formula 1, and pharmaceutically acceptable salts thereof , where X denotes SO, R1 denotes H, R2 denotes H or a residue selected from C1-C10alkyl, which is optionally substituted with one or more residues selected from OR2.1, where R2.1 denotes H or C1-C6alkyl, R2.2 and R2.3 independently denote H or C1-C6alkyl, where Het is a 6-member monocyclic, saturated heterocycle containing 1 heteroatom selected from N or O, and where the hetaryl is a 5-11-member mono- or bicyclic, optionally anellated heteroaryl containing 1, 2 or 3 heteroatoms independently selected from N, S or O, and where the cycloalkyl can be saturated, or R2 denotes a monocyclic C3-cycloalkyl, which is optionally substituted with a residue selected from a branched or linear C1-C6alkanol, C1-C3alkylene-OR2.1, or R2 denotes phenyl which is optionally substituted with a halogen, or R2 denotes a residue selected from Het and hetaryl, each optionally substituted with one or more residues selected from halogen, OH, oxo group and OR2.1, C1-C6alkyl, and where R3 denotes a bicyclic 9-11-member unsaturated or partially saturated heterocycle which is optionally substituted with one or more residues selected from a group comprising F, O, Br, CF3, CN, OH, methyl, ethyl, propyl, isopropyl, -O-methyl, -O-ethyl, phenyl, NR2.2R2.3, where the phenyl is optionally substituted with F, Cl or Br. The invention also relates to pharmaceutical compositions based on said compounds, having phosphodiesterase 4 (PDE4) inhibiting activity. |
|
Invention relates to novel compounds having the structure or pharmaceutically acceptable salts thereof, where Y is or ; A is -(CH2)6-, cis-CH2CH=CH-(CH2)3- or -CH2C=C-(CH2)3-, where 1 or 2 carbon atoms can be substituted with S or O; or A is -(CH2)m-Ar-(CH2)0-, where Ar is interarylene or heterointerarylene, the sum of m and o is equal to 1, 2, 3 or 4, and where one CH2 can be substituted with S or O; J is C=O, CHOH, CHF, CHCl, CHBr, CF2, CCl2, CBr2 or CHCN; and B is aryl or heteroaryl, substituted with C1-10 oxoalkyl. The invention also relates to a method of treating balding, which involves administering a therapeutically effective amount of said compound to a subject in need of such treatment. |
|
Invention refers to medicine, namely - to dermatology. A method involves the ointment application and the ultrasound exposure. The ointment is methylprednisolone aceponate. The ultrasound exposure has an intensity of 0.7-1.0 Wt/cm2. The exposure length is 2-5 minutes per one field. The duration of a procedure is 12 minutes. The therapeutic course is 7 procedures. |
|
|
Agent for treating gastric mucosa erosions Invention refers to pharmaceutical industry, namely an agent for treating gastric mucosa erosions. The agent for treating gastric mucosa erosions representing a dry alcoholic extract of elevated parts of green violet. |
|
Invention refers to pharmaceutical industry, particularly to a hepatoprotective herbal tea. The hepatoprotective herbal tea that contains black currant leaves, red raspberry leaves, great willow herb, meadowsweet herb in certain proportions. |
|
|
Compositions for preventing or relieving gastrointestinal diseases Invention refers to pharmaceutics, namely to an agent for preventing or relieving gastrointestinal diseases. Compositions for preventing or relieving gastrointestinal diseases consists of two or more herbal therapeutic agents specified in a group of: Bupleuri Radix, Coptidis Rhizoma and Glycyrrhizae Radix which represent an unprocessed extract in a solvent specified in a group consisting of water, alcohols C1-C4 and combinations thereof. The therapeutic agent for preventing or relieving a gastrointestinal disease containing the above composition and a pharmaceutically acceptable carrier or a pharmaceutically acceptable additive. A functionally therapeutic product for preventing or relieving the gastrointestinal disease containing the above composition consisting of two or more herbal unprocessed extracts of Bupleuri Radix, Coptidis Rhizoma and Glycyrrhizae Radix. |
|
Present invention refers to an agent for improving antibacterial action, containing an active ingredient in the form of a fraction of molecular weight 5000 or less, prepared of kombu (seaweed) extract. |
|
|
Invention refers to medicine, namely to pharmaceutical industry, concerns preparing a chlorophyll concentrate of sugar laminaria. A method for preparing the chlorophyll concentrate of grinded sugar laminaria by three extractions in ethanol in a shadowed place; further, cake extract is separated; the extractants are combined; the extragent is distilled; the residue is added with water, filtered through a paper filter; the filtered residue is washed in two-three portions of water, dissolved in 96% ethanol; total chlorophylls are dissolved in sterile olive oil to produce 25% total chlorophyll concentration, residual 96% ethanol is distilled under vacuum; the method is conducted in the specific environment. |
|
Invention refers to medicine, namely gynaecology and may be used for individual selection of the preparations containing the probiotic lactic bacterial strains for effective intravaginal therapy. For this purpose, vaginal epithelial cells are recovered from the patient, released from the accompanying microflora. That is followed by preparing an epithelial cell suspension in a culture medium, and mixed with a suspension of thermally-activated probiotic lactic bacterial strains. Then, the suspension is incubated; the epithelial cell culture fluid filtrate is prepared and added to the suspension of the tested probiotic lactic bacterial strains in ratio 1:7. Concurrently, a reference of the mixture of the epithelial cell culture medium and the suspension of the tested probiotic lactic bacterial strains in ratio 1:7 is prepared. The test and reference samples are incubated, measured for optical density; and a degree of biomass increase in the test sample is related to that in the reference. The preparation containing the probiotic lactic bacterial strains the biomass increase of which under the influence of patient's vaginal epithelial cells is stimulated most is selected form the effective intravaginal therapy. |
|
Invention refers to pharmacological and cosmetic industry, namely to a dermatological agent. The dermatological agent containing antler deer's dry blood plasma, Mumiyo, D-Panthenol, Sea buckthorn oil and additives in certain proportions. |
|
|
Method for prevention of using corticosteroids What is presented is using a composition containing galactooligosaccharide, fructooligosaccharide and uronic acid oligosaccharide in preparing a composition for oral administration into an infant for preventing the local administration of corticosteroids and/or preventing the administration of a calcineurin inhibitor into the above infant, wherein uronic acid oligosaccharide represents a pectin degradation product and/or an alginate degradation product, and wherein using the corticosteroids and/or administering the calcineurin inhibitor is applicable for treating eczema, infantile eczema, atopic dermatitis, dermatitis herpetiformis, contact dermatitis, seborrheic dermatitis, neurodermatitis, psoriasis and intertrigo. Particularly, the composition is a nutritional composition. |
|
|
Prostaglandin-based broncholytic drug Invention refers to medicine, namely to pulmonology, and concerns a drug for treating inflammatory and obstructive respiratory diseases, particularly bronchial asthma and obstructive bronchitis, based on 1,3'-dinitroglycerine ester of 11(S),15(S)-dihydroxy-9-keto-5Z,13E-prostadiene acid, possessing a pronounced bronchodilatory effect. What is considered is a method of treating the inflammatory and obstructive respiratory diseases using the drug based on 1,3'-dinitroglycerine ester of 11(S),15(S)-dihydroxy-9-keto-5Z,13E-prostadiene acid. |
|
Incapsulated hepatocyte composition Invention refers to pharmaceutical industry, namely to a microcapsules for preventing or treating hepatic disorders. The microcapsules for preventing or treating hepatic disorders containing a capsule coating, an encapsulating suspension of a therapeutically effective hepatocyte count in a physical contact with a hepatocyte-stimulating amount of erythropoietin. A method for preparing microcapsules involving preparing the suspension of the therapeutically effective hepatocyte count and the hepatocyte-stimulating amount of erythropoietin to bring them in physical contact with each other, and encapsulating the suspension of hepatocytes and erythropoietin in a biologically compatible capsule shell so that to form a microcapsule. A method for preventing or treating a hepatic disorder in an individual in need thereof involving administering the microcapsules in the individual in need thereof. The method for introducing the hepatocytes in the individual involving administering the microcapsules in the individual. A method for hepatocyte culture in a culture medium involving hepatocyte culture in the microcapsules in the appropriate culture medium. |
|
Layers for mechanical protection of solid dosage forms Present invention refers to a layer for mechanical protection of dosage forms, containing two or more plasticizing agents, wherein the first plasticizing agent represents first polyethylene glycol of average molecular weight between 3000 and 6000, and the second plasticising agent represents second polyethylene glycol of average molecular weight between 5000 to 7000. The above layer for mechanical protection is found on an enteric coated granule. The declared invention also refers to the pharmaceutically acceptable enteric solid dosage forms comprising the layer for mechanical protection, and to methods for preparing and using the above layer. |
|
Pharmaceutical composition containing vitamin d analogue and mixed co-solvent and surfactant Invention refers to pharmaceutical industry, and represents a local skin composition which is an oil-in-water-in-oil emulsion containing a water phase with a dispersed lipophilic phase containing calcipotriol or monohydrate in the dissolved form; a non-ionic surfactant specified in a group consisting of polyethylene glycol glycerides and C6-20 fatty acids, polyoxyethylene C8-20 alkyl ethers or polysorbates and a lower alkanol as a co-solvent; the above water phase is dispersed in a pharmaceutically acceptable anhydrous lipophilic carrier or base. |
|
Method of correcting microcirculatory disorders in case of chronic catarrhal gingivitis in people Invention relates to field of medicine, namely to dentistry, physiotherapy. Method includes influence by defocused shock wave through applications of enterosorbent "BS-P", applied on upper and lower jaw. Influence by shock wave is realised through soft tissues of maxillofacial area. Influence is performed with pulse duration 0.4-0.7 mcs, pulse frequency 90 Hz, pressure amplitude from 6 to 9 MPa, total number of pulses 1000. Procedures are carried out every second day. Course includes 7-10 sessions. |
|
|
Invention relates to 4-(azacycloalkyl)benzene-1,3-diol compounds of general formula (I) given below: |
|
Method for early deep burn healing Invention relates to medicine and may be used for early deep burn healing. That is ensured by taking a patient's healthy tissue transplant. A cell suspension is prepared in the laboratory environment and applied together with fibrin glue (Tissucol). The intraoperative use of the invention enables reducing the length of staying on the operative table. Besides, the cell suspension applied together with fibrin glue is presented by the integral cell elements that promotes the better adhesion and the functional state continuance. |
|
|
Method of treating and preventing nasal obstruction in patients suffering polypous rhinosinusitis Invention refers to medicine, namely to otorhinolaryngology, and may be used for treating and preventing a nasal obstruction in the patients with polypous rhinosinusitis. That is ensured by prescribing Singulair to be administered per os in a dose of 5 mg daily for 5 months with underlying topic corticosteroids. |
|
|
Invention refers to medicine, namely to rheumatology and may be used for treating the patients with ostheoarthrosis fulfilling driving and supervision functions with Theraflex Advance, Theraflex and Theraflex M cream. The treatment is two-staged, including 17-day hospital treatment and six-month outpatient treatment. The hospital treatment involves Theraflex Advance 2 tablets 3 times a day in a combination with local skin applications of Theraflex M cream 2-3 times a day as a 2-3 cm strip rubbed until absorbed completely. The outpatient treatment involves prescribing Theraflex 1 capsule 3 times a day for the first three weeks, further 1 capsule 2 times a day in a combination with Theraflex M cream locally applied on the skin 2-3 times a day as a 2-3 cm strip rubbed until absorbed completely. |
Another patent 2491658.